AEON Biopharma shares surge 11.87% intraday on $22M fundraise and positive ABP-450 biosimilarity data ahead of FDA meeting.

AEON Biopharma surged 11.87% intraday following the announcement of two key developments: a $22 million fundraising through a private placement and convertible note exchange with Daewoong, which will eliminate nearly all outstanding debt and extend cash runway to Q2 2026, and robust biosimilarity data showing 100% amino acid sequence identity and functional similarity between ABP-450 and BOTOX®. These events, coupled with positive analytical data submitted to the FDA ahead of a critical Type 2a meeting, strengthened investor confidence in the company’s path to biosimilar approval and de-risked its U.S. program. The debt reduction and capital infusion, alongside strong scientific progress, positioned AEON to advance its biosimilar pipeline with enhanced financial stability and regulatory alignment.